Evotec
Stephen East has extensive experience in the field of innovation and efficiency, currently serving as VP Head of Innovation Efficiency at Evotec since April 2003, where previous roles included Senior Innovation Efficiency Leader and Project Leader. In addition to this, Stephen has been a Committee Member and Conference Organiser at SCI® Where Science Meets Business since September 2001 and was an Editorial Board Member for the journal Expert Opinion in Therapeutic Patents from June 2009 to June 2014. Prior experience includes positions at British Biotechnology PLC, Imperial College London, and the University of Pennsylvania, where Stephen worked as a Scientist, Senior Scientist, and Post-doctoral Research Assistant. Stephen holds a Doctor of Philosophy (PhD) in Organic Chemistry and a Bachelor of Science (BSc) in Chemistry, both from the University of Bristol.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.